Vertex Pharmaceuticals (VRTX) EPS (Weighted Average and Diluted) (2009 - 2026)
Vertex Pharmaceuticals' quarterly EPS (Weighted Average and Diluted) came in at $4.02 in Q1 2026, up 61.45% year-on-year from $2.49 in Q1 2025, and down 13.36% quarter-over-quarter from $4.64 in Q4 2025.
Vertex Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 18 years, with the latest figure at $4.02 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 61.45% year-over-year to $4.02; the trailing twelve-month figure through Mar 2026 stood at $16.85 (up 533.16% YoY), and the FY2025 full-year result was $15.32, up 836.54% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $4.02, down from $4.64 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $4.64 in Q4 2025, with the low at -$13.92 in Q2 2024.
- Average EPS (Weighted Average and Diluted) over 5 years is $2.58, with a median of $3.59 recorded in 2022.
- Year-over-year, EPS (Weighted Average and Diluted) jumped 1103.85% in 2022 and plunged 495.45% in 2024.
- Tracing VRTX's EPS (Weighted Average and Diluted) over 5 years: stood at $3.14 in 2022, then advanced by 18.15% to $3.71 in 2023, then slipped by 4.85% to $3.53 in 2024, then jumped by 31.44% to $4.64 in 2025, then dropped by 13.36% to $4.02 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $4.02 (Q1 2026), $4.64 (Q4 2025), and $4.2 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.51 |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | -2.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.02 |
| Dec 31, 2025 | 4.64 |
| Sep 30, 2025 | 4.20 |
| Jun 30, 2025 | 3.99 |
| Mar 31, 2025 | 2.49 |
| Dec 31, 2024 | 3.53 |
| Sep 30, 2024 | 4.01 |
| Jun 30, 2024 | -13.92 |
| Mar 31, 2024 | 4.21 |
| Dec 31, 2023 | 3.71 |
| Sep 30, 2023 | 3.97 |
| Jun 30, 2023 | 3.52 |
| Mar 31, 2023 | 2.69 |
| Dec 31, 2022 | 3.14 |
| Sep 30, 2022 | 3.59 |
| Jun 30, 2022 | 3.13 |
| Mar 31, 2022 | 2.96 |
| Dec 31, 2021 | 2.98 |
| Sep 30, 2021 | 3.28 |
| Jun 30, 2021 | 0.26 |
| Mar 31, 2021 | 2.49 |
| Dec 31, 2020 | 2.30 |
| Sep 30, 2020 | 2.53 |
| Jun 30, 2020 | 3.18 |
| Mar 31, 2020 | 2.29 |
| Dec 31, 2019 | 2.23 |
| Sep 30, 2019 | 0.22 |
| Jun 30, 2019 | 1.03 |
| Mar 31, 2019 | 1.03 |
| Dec 31, 2018 | 5.97 |
| Sep 30, 2018 | 0.50 |
| Jun 30, 2018 | 0.80 |
| Mar 31, 2018 | 0.81 |
| Dec 31, 2017 | 0.39 |
| Sep 30, 2017 | -0.41 |
| Jun 30, 2017 | 0.07 |
| Mar 31, 2017 | 0.99 |
| Dec 31, 2016 | 0.13 |
| Sep 30, 2016 | -0.16 |
| Jun 30, 2016 | -0.26 |
| Mar 31, 2016 | -0.17 |
| Dec 31, 2015 | -0.31 |
| Sep 30, 2015 | -0.39 |
| Jun 30, 2015 | -0.78 |
| Mar 31, 2015 | -0.83 |
| Dec 31, 2014 | -0.74 |
| Sep 30, 2014 | -0.72 |
| Jun 30, 2014 | -0.68 |
| Mar 31, 2014 | -1.00 |
| Dec 31, 2013 | 0.19 |
| Sep 30, 2013 | -0.54 |
| Jun 30, 2013 | -0.26 |
| Mar 31, 2013 | -1.43 |
| Dec 31, 2012 | -0.35 |
| Sep 30, 2012 | -0.27 |
| Jun 30, 2012 | -0.31 |
| Mar 31, 2012 | 0.43 |
| Dec 31, 2011 | 0.74 |
| Sep 30, 2011 | 1.02 |
| Mar 31, 2011 | -0.87 |
| Dec 31, 2010 | -0.90 |
| Sep 30, 2010 | -1.04 |
| Jun 30, 2010 | -1.00 |
| Mar 31, 2010 | -0.83 |
| Dec 31, 2009 | -0.86 |
| Sep 30, 2009 | -0.84 |
| Jun 30, 2009 | -0.99 |
| Mar 31, 2009 | -1.04 |